2.06
+0.41(+24.85%)
Currency In USD
| Previous Close | 1.65 |
| Open | 1.63 |
| Day High | 2.06 |
| Day Low | 1.63 |
| 52-Week High | 28.6 |
| 52-Week Low | 1.52 |
| Volume | 620,885 |
| Average Volume | 610,123 |
| Market Cap | 4.16M |
| PE | -0.11 |
| EPS | -19.5 |
| Moving Average 50 Days | 3.21 |
| Moving Average 200 Days | 6.73 |
| Change | 0.41 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $4.92 as of December 04, 2025 at a share price of $2.06. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $37.9 as of December 04, 2025 at a share price of $2.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
GlobeNewswire Inc.
Yesterday at 1:30 PM GMT
Findings further validate FABP5 inhibition and strengthen the therapeutic potential of Artelo’s FABP5 platform for mood and stress-related disordersSOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Ar
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Nov 12, 2025 1:00 PM GMT
Encouraging Clinical Progress, Including Positive Interim Phase 2 Results for the Treatment of Cancer Anorexia Cachexia SyndromeSOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharma
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPsSOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-sign